Swiss Diabetes Registry for patients with diabetes
Swiss Diabetes Registry - SwissDiab Study, a Prospective Cohort Study of Patients With Diabetes in Switzerland
This study is collecting information from diabetes patients in Switzerland to see how well their treatment matches current guidelines and to improve care for everyone with diabetes.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 1500 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | Insel Gruppe AG, University Hospital Bern Academic / other |
| Locations | 4 sites (Bern and 3 other locations) |
| Trial ID | NCT01179815 on ClinicalTrials.gov |
What this trial studies
The Swiss Diabetes Registry - SwissDiab Study is a prospective cohort study that aims to collect comprehensive data from nearly all patients with diabetes mellitus treated at participating centers in Switzerland. By utilizing an internet-based electronic database, the study evaluates the current standard of care and treatment outcomes for patients with type 1, type 2, and other forms of diabetes. This observational study seeks to identify discrepancies between recommended treatment guidelines and actual patient care in both specialty clinics and community settings. The findings will help inform future diabetes management strategies and improve patient well-being.
Who should consider this trial
Good fit: Ideal candidates for this study are adults over 18 years old diagnosed with any form of diabetes mellitus.
Not a fit: Patients with gestational diabetes or those unable to provide informed consent may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could lead to improved diabetes management and better health outcomes for patients.
How similar studies have performed: Other observational studies have shown success in identifying gaps in diabetes care, making this approach both relevant and necessary.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Age \> 18 years * Diagnosis of diabetes mellitus according to ADA criteria * Informed consent Exclusion Criteria: * Patients with gestational diabetes mellitus, patients unable to give informed consent, legally incompetent or incapable to comply with the study terms and conditions as well as patients with significantly reduced life expectancy (\<1 year) will be excluded
Where this trial is running
Bern and 3 other locations
- Universitätspoliklinik für Endokrinologie, Diabetologie und Klinische Ernährung, Inselspital Bern — Bern, Switzerland (Recruiting)
- Service d'endocrinologie, diabétologie et métabolisme — Lausanne, Switzerland (Recruiting)
- Klinik für Endokrinologie, Diabetologie, Osteologie und Stoffwechselerkrankungen, Kantonsspital St.Gallen — Sankt Gallen, Switzerland (Recruiting)
- Klinik für Endokrinologie, Diabetologie und Klinische Ernährung, Universitätsspital Zürich — Zurich, Switzerland (Recruiting)
Study contacts
- Principal investigator: Michael Brändle, Prof. — Div. of Endocrinology, Diabetes and Clinical Nutrition, Kantonsspital St. Gallen
- Study coordinator: Markus Laimer, PD Dr. med.
- Email: Markus.Laimer@insel.ch
- Phone: +41 31 632 30 62
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.